CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Jun. 30, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	[1]	$ 1,784	$ 1,139	[2]
Short-term investments	[1]	11,128	17,694
Trade accounts receivable, less allowance for doubtful accounts: 2019—$540; 2018—$541	[1]	9,793	8,025
Inventories	[1],[3]	8,233	7,508
Current tax assets	[1]	3,723	3,374
Other current assets	[1]	2,535	2,461
Assets held for sale	[1]	9,877	9,725
Total current assets	[1]	47,073	49,926
Long-term investments	[1]	2,905	2,767
Property, plant and equipment, less accumulated depreciation: 2019—$16,389; 2018—$16,591	[1]	13,521	13,385
Identifiable intangible assets, less accumulated amortization	[1],[4]	33,024	35,211
Goodwill	[1]	53,352	53,411
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,935	1,924
Other noncurrent assets	[1]	4,388	2,799
Total assets	[1]	156,199	159,422
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2019—$2,139; 2018—$4,776	[1]	10,507	8,831
Trade accounts payable	[1]	4,002	4,674
Dividends payable	[1]	1,991	2,047
Income taxes payable	[1]	1,536	1,265
Accrued compensation and related items	[1]	1,875	2,397
Other current liabilities	[1]	10,110	10,753
Liabilities held for sale	[1]	2,009	1,890
Total current liabilities	[1]	32,030	31,858
Long-term debt	[1]	36,168	32,909
Pension benefit obligations, net	[1]	4,982	5,272
Postretirement benefit obligations, net	[1]	1,310	1,338
Noncurrent deferred tax liabilities	[1]	3,180	3,700
Other taxes payable	[1]	12,421	14,737
Other noncurrent liabilities	[1]	6,183	5,850
Total liabilities	[1]	96,274	95,664
Commitments and Contingencies	[1]
Preferred stock	[1]	18	19
Common stock	[1]	468	467
Additional paid-in capital	[1]	86,963	86,253
Treasury stock	[1]	(110,786)	(101,610)
Retained earnings	[1]	94,440	89,554
Accumulated other comprehensive loss	[1]	(11,535)	(11,275)
Total Pfizer Inc. shareholders’ equity	[1]	59,568	63,407
Equity attributable to noncontrolling interests	[1]	357	351
Total equity	[1],[5]	59,924	63,758
Total liabilities and equity	[1]	$ 156,199	$ 159,422

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery and market demand, partially offset by a decrease due to foreign exchange.

[4] The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization and intangible asset impairment charges, partially offset by additions for the period. See Note 4 for additional information on intangible asset impairments.

[5] Amounts may not add due to rounding.